Bruce D Cheson
Academic and Community Cancer Research United · Georgetown University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bruce D Cheson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02758717 · Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin LymphomaAcademic and Community Cancer Research United · active not recruiting · Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma · principal investigator
- Ph1NCT00864942 · Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)Georgetown University · completed · Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma · principal investigator
- Ph2NCT00860457 · Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)Georgetown University · completed · Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer and Leukemia Group BU10CA077597 · NCI · GEORGETOWN UNIVERSITY · fiscal years 2012 to 2013 · $85,066 awarded in 2013Same name and institution; not confirmed by an ID
- PROSPECTIVE STUDY EVALUATING ZAP-70 EXPRESSION, CD38 EXPRESSION & PROGNOSIS- CLLM01RR023942 · NCRR · GEORGETOWN UNIVERSITY · fiscal years 2007 · $43,867 awarded in 2007Same name and institution; not confirmed by an ID
- Evaluating zap-70 expression, CD38 expression and prognosis in CLLM01RR013297 · NCRR · GEORGETOWN UNIVERSITY · fiscal years 2004 · $3,507 awarded in 2004Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT02758717
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:17 UTC. The ranking covers the 200 most relevant of 107 PubMed records, and a shared surname and initials can bring in a namesake. All 107 on PubMed
- Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.N Engl J Med · 20141,390 citationsRCR 36.7
- Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.J Clin Oncol · 20121,170 citationsRCR 30.4
- Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.N Engl J Med · 2000780 citationsRCR 15.9
- Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).J Clin Oncol · 2013393 citationsRCR 12.3
- 358 citationsRCR 14.1
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.Lancet Oncol · 2018324 citationsRCR 10.2
- Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.J Clin Oncol · 2008295 citationsRCR 7.0
- 288 citationsRCR 8.7
- 274 citationsRCR 5.4
- Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.J Clin Oncol · 2008247 citationsRCR 5.7